About Cliff Gorski

This author has not yet filled in any details.
So far Cliff Gorski has created 45 blog entries.

Mitochondria are moving into the mainstream scientific limelight, thanks in large part to Douglas Wallace, PhD, the “world’s biggest mitochondriac” who is galvanizing research on the Penn and CHOP campuses into the role of cellular energy in disease.”

2017-10-19T10:13:58+00:00

Click here to read article.

Mitochondria are moving into the mainstream scientific limelight, thanks in large part to Douglas Wallace, PhD, the “world’s biggest mitochondriac” who is galvanizing research on the Penn and CHOP campuses into the role of cellular energy in disease.” 2017-10-19T10:13:58+00:00

Dr Mark Korson Joins VMP Genetics Expanding Metabolic Medicine Services to Physicians, Hospitals, and Institutions Worldwide

2017-10-10T14:36:28+00:00

VMP Genetics and Dr. Fran Kendall, pioneers in rare genetics and telemedicine, are pleased to announce that Dr. Mark Korson has joined VMP as the Director of Physician Support and Educational Services divisions.  Expanding these two divisions extends our reach beyond current direct patient care and remote second opinion services into medical consultation to [...]

Dr Mark Korson Joins VMP Genetics Expanding Metabolic Medicine Services to Physicians, Hospitals, and Institutions Worldwide 2017-10-10T14:36:28+00:00

Stealth BioTherapeutics Granted Orphan Drug Designation of Elamipretide for Treatment of Patients with Primary Mitochondrial Myopathy

2017-10-02T11:02:06+00:00

BOSTON, October 2, 2017 /PRNewswire/ -- Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to Stealth's investigational drug candidate, elamipretide, for the treatment of patients with primary mitochondrial myopathy (PMM). [...]

Stealth BioTherapeutics Granted Orphan Drug Designation of Elamipretide for Treatment of Patients with Primary Mitochondrial Myopathy 2017-10-02T11:02:06+00:00